Addex Therapeutics Ltd
ADXN
$8.38
-$0.61-6.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -205.73% | 174.52% | 164.32% | 146.34% | 133.19% |
| Total Depreciation and Amortization | -31.94% | 1,521.80% | 1,554.20% | 118.21% | -18.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 122.13% | -584.20% | -580.07% | -550.33% | -532.41% |
| Change in Net Operating Assets | 279.88% | -241.95% | -577.64% | 98.54% | 69.96% |
| Cash from Operations | 86.91% | 52.41% | 31.84% | 40.81% | 23.99% |
| Capital Expenditure | 31.82% | 70.00% | 80.52% | 53.97% | 63.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.45% | -- | -- | -- | 139,383.78% |
| Cash from Investing | -100.48% | 102,820.00% | 66,801.30% | 81,888.89% | 215,045.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 97.25% | 96.25% | 73.85% | 49.59% | 24.05% |
| Issuance of Common Stock | -98.38% | -99.71% | -89.77% | -89.10% | -93.72% |
| Repurchase of Common Stock | 100.00% | 47.47% | 45.51% | 59.31% | 59.68% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 173.98% | -97.98% | -101.07% | -101.13% | -102.24% |
| Cash from Financing | 168.60% | -99.12% | -97.90% | -98.98% | -101.51% |
| Foreign Exchange rate Adjustments | 79.89% | 93.75% | 128.41% | 60.60% | 71.94% |
| Miscellaneous Cash Flow Adjustments | -- | 196.68% | -- | -- | -- |
| Net Change in Cash | 72.12% | 128.57% | 80.16% | 72.24% | -136.13% |